Your browser doesn't support javascript.
loading
The CD112R/CD112 axis: a breakthrough in cancer immunotherapy.
Zeng, Taofei; Cao, Yuqing; Jin, Tianqiang; Tian, Yu; Dai, Chaoliu; Xu, Feng.
Affiliation
  • Zeng T; Department of General Surgery, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, 110004, China.
  • Cao Y; Department of General Surgery, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, 110004, China.
  • Jin T; Department of General Surgery, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, 110004, China.
  • Tian Y; Department of General Surgery, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, 110004, China.
  • Dai C; Department of General Surgery, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, 110004, China.
  • Xu F; Department of General Surgery, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, 110004, China. xuf@sj-hospital.org.
J Exp Clin Cancer Res ; 40(1): 285, 2021 Sep 10.
Article in En | MEDLINE | ID: mdl-34507594
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Cell Surface / Immunotherapy / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Exp Clin Cancer Res Year: 2021 Document type: Article Affiliation country: China Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Cell Surface / Immunotherapy / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Exp Clin Cancer Res Year: 2021 Document type: Article Affiliation country: China Country of publication: United kingdom